Hepatitis B and CML - Participate in the survey of practice

Please share your experiences

Guidance from hepatologists suggests patients with CML on TKI therapy and HBV should receive antivirals and that viral load should be monitored. However, there are mixed messages in the literature and guidelines and clear practical guidance on screening and monitoring for HBV in these patients is lacking. Most hematology centres have very few CML patients who are Hepatitis B positive and therefore again, experience and practical guidance for HBV reactivation for people also being treated for CML is limited.

On the initiative of Professor Dragana Milojkovic (Imperial College London, UK), the iCMLf has formed a HBV and CML Working Group*. This group will collect and collate global experiences of physicians treating CML and HBV with the aim of developing recommendations on monitoring and treatment of HBV for patients with CML. 

The iCMLf Hepatitis B virus (HBV) Screening and Management Survey is now open. 

The iCMLf Hepatitis B Virus (HBV) prophylaxis on TKI therapy survey of practice looks at:

• CML patients in clinical practice who reactivated HBV
• Screening at baseline prior to first TKI therapy
• Management of patients with past history of HBV infection
• Specific guidelines for HBV antiviral use for CML patients on TKI therapy

We would be delighted to learn from you. 

Please share your experiences with us by participating in the survey here

The survey will be open until 27th February. 

* iCMLf HBV Working Group: Dragana Milojkovic, Chair (UK), Katia Pagnano (Brazil), Qian Jiang (China), Delphine Réa (Fance), Hemant Malhotra (India), Giuseppe Saglio (Italy), Fausto Castagnetti (Italy), Salam al Kindi (Oman), Mohamed Yassin (Quatar), Charles Chuah (Singapore), Jorge Cortes (USA)